Direct-acting antivirals failed to reduce the incidence of hepatocellular carcinoma occurrence in hepatitis C virus associated cirrhosis: A real-world study

doi:10.4254/wjh.v16.i1.41

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1978)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

1296

Figures (1-4)

145

Tables (1-3)

120

Sum=1627

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

201

Sum=287

Jan 27, 2024 (publication date) through Jul 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Jan 27, 2024; 16(1): 41-53
Published online Jan 27, 2024. doi: 10.4254/wjh.v16.i1.41

Table 2 Changes of laboratory parameters before and after sustained virologic response in the direct-acting antiviral agents treatment group (n = 236)

Variables	Before DAA	After DAA	t/Z/χ²	P value
ALT (U/L)	52 (34, 84.25)	20.5 (16, 32)	12.962	0
AST (U/L)	59.5 (40, 83.5)	26 (20.2, 39)	14.351	0
γ-GT (U/L)	58 (34.75, 108.5)	34 (23, 54)	8.691	0
ALP (U/L)	86 (65.75, 113.25)	83.9 (64, 115)	2.236	0.025
TP (g/L)	71.93 ± 8.23	73.62 ± 7.88	-2.267	0.024
ALB (g/L)	38.78 ± 6.22	42.93 ± 7.08	-6.755	0
TBIL (μmol/L)	18.6 (14.5, 27.5)	23.7 (13.3, 41)	-1.452	0.146
BUN (mmol/L)	4.98 ± 2.24	5.83 ± 3.70	-2.969	0.003
GLU (mmol/L)	6.34 ± 1.98	6.93 ± 2.44	-2.717	0.007
PT (s)	14.41 ± 2.16	14.30 ± 6.35	0.16	0.873
INR	1.27 ± 1.22	1.21 ± 0.56	0.444	0.557
WBC (10⁹/L)	4.39 ± 1.69	4.93 ± 2.13	-3.066	0.002
RBC (10¹²/L)	4.14 ± 0.75	4.27 ± 0.79	-1.803	0.072
HGB (g/L)	130.33 ± 23.05	131.91 ± 25.07	-0.706	0.481
PLT (10⁹/L)	108.20 ± 61.66	123.45 ± 65.98	-2.57	0.01
CEA (ng/mL)	3.3 (2.22, 4.89)	3.34 (2.3, 5.27)	-0.111	0.911
AFP (ng/mL)	9.38 (5.31, 19.67)	5.81 (3.6, 9.02)	9.683	0
PIVKA-II (mAU/mL)	24 (18,32)	28 (20,41)	-1.958	0.05
CAP (dB/m)	232.76 ± 45.35	239.56 ± 45.35	-2.062	0.04
LSM (kPa)	26.15 ± 16.90	20.55 ± 16.95	3.499	0.001

SVR: Sustained virologic response; DAA: Direct-acting antiviral agents; HCV RNA was calculated by denary logarithm expressed as lg (HCV RNA); CEA: Carcinoembryonic antigen; AFP: Alpha fetoprotein; PIVKA-II: Vitamin K Absence or Antagonist-II; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; γ-GT: γ-alanine transferase; ALP: Alkaline phosphatase; TP: Total protein; ALB: Albumin; TBIL: Total bilirubin; BUN: Renal function; GLU: Blood glucose; PT: Prothrombin time; INR: International standardized ratio of prothrombin time; WBC: White blood cell; RBC: Red blood cell; HGB: Hemoglobin; PLT: Platelet; CAP: Controlled attenuation parameter; LSM: Liver stiffness measurement.

Citation: Tao XM, Zeng MH, Zhao YF, Han JX, Mi YQ, Xu L. Direct-acting antivirals failed to reduce the incidence of hepatocellular carcinoma occurrence in hepatitis C virus associated cirrhosis: A real-world study. World J Hepatol 2024; 16(1): 41-53
URL: https://www.wjgnet.com/1948-5182/full/v16/i1/41.htm
DOI: https://dx.doi.org/10.4254/wjh.v16.i1.41